1 Non-GAAP cost of product revenues excludes the amortization of licensed intellectual property for Iclusig relating to the acquisition of the European business of ARIAD Pharmaceuticals, Inc. and the ...
1 Non-GAAP cost of product revenues excludes the amortization of licensed intellectual property for Iclusig relating to the acquisition of the European business of ARIAD Pharmaceuticals, Inc. and the ...
Increasing the per annum production run-rate at the Elk Creek complex to close to 3 million tons increased from ~2.3 million tons in 2024. At the Berwind mine ramping up production at the 3rd section ...
Following first-quarter results, Moderna maintained its 2025 outlook and lowered operating cost guidance for 2026-27, with GAAP costs expected to fall by $1.4 billion-$1.7 billion between 2025 and ...
Meets or exceeds all third quarter guidance metrics GAAP Net income of $5.2 million reflects $35 million year-over-year improvement GAAP EPS of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback